Rigel Pharmaceuticals RIGL Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's available-for-sale debt securities - unrealized loss position (<12 months)?
- Rigel Pharmaceuticals (RIGL) reported available-for-sale debt securities - unrealized loss position (<12 months) of $95.28M in Q1 2026.
- What does available-for-sale debt securities - unrealized loss position (<12 months) mean?
- This tracks debt securities in an unrealized loss position for less than one year, typically reflecting short-term market fluctuations. It helps distinguish between temporary market volatility and more persistent credit issues within the investment portfolio. Monitoring this provides a view of the immediate impact of interest rate changes on the balance sheet.